Institute of Physiology

Keyphrases

1. Hemodialysis Patients 100%
2. Chronic Kidney Disease 90%
3. Wood Smoke 68%
4. Cigarette Smoking 61%
5. Transient Receptor Potential Vanilloid 1 (TRPV1) 55%
6. 95% Confidence Interval 54%
7. Lung 51%
8. Maintenance Hemodialysis Patients 50%
9. National Cohort Study 46%
10. Chloride Channel 44%
11. Kidney Disease Progression 40%
12. Capsaicin 36%
13. Glucosamine 32%
14. Phosphorylation 31%
15. ClC-1 31%
16. Reactive Oxygen Species 31%
17. Erythropoietin 31%
18. Heme oxygenase-1 (HO-1) 31%
19. All-cause Mortality 30%
20. Induced Pluripotent Stem Cells (iPSCs) 30%
21. Interleukin-8 30%
22. Taiwan 29%
23. Lung Inflammation 29%
24. NADPH Oxidase 28%
25. Protein Kinase C 28%
26. RhEPO 28%
27. Hazard Ratio 28%
28. Soluble Epoxide Hydrolase 27%
29. Adjusted Hazard Ratio 27%
30. Matrix metalloproteinase-2 (MMP-2) 27%
31. Chronic Kidney Disease Patient 26%
32. Cigarette Smoke Extract 26%
33. End-stage Renal Disease 26%
34. Amygdala 26%
35. Rat Model 25%
36. Oxidative Stress 25%
37. ClC Channel 25%
38. Anemia 25%
39. Aryl Hydrocarbon Receptor 24%
40. Acute Kidney Injury 24%
41. Macrophages 24%
42. Hemodialysis 24%
43. Cardiovascular Mortality 24%
44. Reflex 24%
45. Apoptosis 24%
46. Molecular Mechanism 23%
47. Arteriovenous Fistula 23%
48. Ca2+ 23%
49. Carotid Body 22%
50. Cyclooxygenase-2 22%
51. Indoxyl Sulfate 22%
52. Substance P 22%
53. Guinea pig 21%
54. NF-B 21%
55. Relaxin 21%
56. COVID-19 21%
57. Rapidly Adapting Receptor 20%
58. Estimated Glomerular Filtration Rate 20%
59. Hydroxyl Radical ([rad]OH) 20%
60. Anesthetized Rats 20%
61. Endothelial Nitric Oxide Synthase (eNOS) 19%
62. Dialysis 19%
63. Inflammation 19%
64. Follicle-stimulating Hormone 19%
65. Acid Activation 19%
66. Lipopolysaccharide 19%
67. Transforming Growth Factor-β 19%
68. Curcumin 19%
69. High Risk 19%
70. Erythropoiesis-stimulating Agents 19%
71. Risk Factors 19%
72. Astrocytes 18%
73. TMEM16A 18%
74. Decoy Receptor 3 (DcR3) 18%
75. ATP-binding Cassette Transporter A1 (ABCA1) 18%
76. AMP-activated Protein Kinase 18%
77. Liver 18%
78. Protein Expression 18%
79. Ovarian Granulosa Cells 18%
80. Pulmonary C-fibers 18%
81. Mechanical Ventilation 17%
82. Dialysis Patients 17%
83. Interleukin-1β 17%
84. Angiotensin Receptor Blockers 17%
85. A431 16%
86. Inhibitory Effect 16%
87. Mitogen-activated Protein Kinase 16%
88. Clinical Outcomes 16%
89. C-fiber Afferents 16%
90. Attenuation 16%
91. Nicotine 16%
92. Glutamate 16%
93. Tachykinin 16%
94. Signaling Pathway 16%
95. Kidney 15%
96. Airway Hyperresponsiveness 15%
97. Angiotensin-converting Enzyme Inhibitor (ACEi) 15%
98. Type 2 Diabetic Patients 15%
99. Neurotoxicity 15%
100. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 15%